(A Toxicologist’s Guide to the Side of Cannabis No One Talks About — But Should)

The University of Arizona Health Sciences recently reported that cannabis terpenes themselves — not just cannabinoids — may provide measurable pain relief and contribute to the “entourage effect.”

https://healthsciences.arizona.edu/news/releases/study-shows-cannabis-terpenes-provide-pain-relief-contribute-entourage-effect

But here’s the twist the headlines are missing:

 Terpenes also interact with drug-metabolizing enzymes — and chronic cannabis use may quietly change how prescription medications behave in the body.

If you work in toxicology, product development, regulatory strategy, or cannabinoid formulation, memorize this:

 Cannabis terpenes aren’t aromas. They’re active chemicals with drug-interaction potential — and treating them like “flavor notes” is a design flaw.

 What Terpenes Are Really Doing in Your Body

Terpenes such as linalool, limonene, myrcene, pinene, and beta-caryophyllene are pharmacologically active small molecules that interact with:

CNS receptors

Ion channels

Inflammatory pathways

CYP450 drug-metabolizing enzymes

P-glycoprotein transporters

The University of Arizona found that terpenes can mimic cannabinoids and provide pain relief — which means they act like drugs.
And when you mix drugs with drugs… toxicologists wake up.

 The Toxicology Reality: Terpenes + Medications = Surprise Interactions
1. CYP450 Inhibition and Induction — The Hidden Mechanism

Many terpenes directly affect the enzymes that metabolize most pharmaceuticals.

Examples:

Terpene Affected CYP Enzymes
Limonene        CYP2C9, CYP3A4
Myrcene CYP1A2
Pinene  CYP2B6
Linalool        CYP2C19

This can raise blood levels of:

SSRIs / SNRIs

Benzodiazepines

Anticoagulants

Beta blockers

Anti-epileptics

Opioids

Diabetes medications

Statins

If you take ≥5 medications (clinical polypharmacy), adding chronic terpene exposure is basically adding another drug to your regimen… silently.

 This is the brutal side effect no one is talking about:
Terpenes may alter medication safety without the user — or clinician — understanding why.

2. Terpene Concentrations Have Skyrocketed

Modern cannabis products are engineered for:

Higher terpene counts

Boosted terpene ratios

Added terpene isolates

Aerosolized/vape-ready terpene formulations

This is not the trace-terpene cannabis of the 1970s.
This is chemically enriched cannabis, which in toxicology terms means:

 Higher dose → Higher exposure → Higher interaction potential

3. Terpenes Cross the Blood-Brain Barrier Easily

Terpenes are lipophilic — they slip into the brain extremely well.

This increases interaction potential with CNS medications:

Antidepressants

Anxiolytics

Antipsychotics

Sedatives

ADHD medications

For product developers, the message is simple:

 High-terpene formulations require CNS safety data.

 Practical & Tactical Takeaways for Developers and Clinicians
1. Build Terpene Toxicology Screens Into R&D

For any terpene-containing product (cannabis, hemp, wellness supplements):

CYP inhibition studies

Phase II metabolism

P-gp transport effects

Dose accumulation

Vapor vs edible vs oral exposure differences

2. Treat Terpenes as Active Ingredients

Stop calling them “inactive.”

Regulatory toxicology implications:
You need:

Dose justification

Safety margins

Risk assessments

Interaction screening

3. Update Labeling and Consumer Warnings

For terpene-rich or terpene-infused products:

“May interact with medications metabolized by CYP3A4 or CYP2C9.”

“Consult a clinician if using anticoagulants or CNS-active drugs.”

4. Model Real-World Use — Not Laboratory Fantasy

People use cannabis daily, with:

Prescription drugs

Alcohol

Supplements

Your safety model must reflect that exposure landscape.

5. Use FDA-Compliant Communication

Follow 21 CFR 201 & 202 for risk statements.
Stay in compliance while providing real safety information.

 My Professional Opinion

As a toxicologist, here’s the truth:

The cannabis industry has been stuck in a THC vs CBD debate while ignoring the biologically active compounds that surround them.

That era is over.

 Terpenes are drugs. Treat them like drugs.

High-terpene products need:

Full toxicology characterization

Clearer labeling

Pharmacokinetic evaluation

Pediatric exposure evaluation

Inhalation safety profiles

Ignoring terpene–drug interactions today will become tomorrow’s preventable safety headline.

If a product is marketed as “high-terpene,” it deserves high scrutiny.

The Bottom Line

The University of Arizona showed that terpenes can relieve pain — great news.

But they also contribute to drug interactions — a critical story for product developers, toxicologists, and regulators.

 The future of cannabis isn’t THC or CBD.
It’s terpene pharmacology — and toxicology must lead that conversation.

The safest, most effective next-generation cannabis products will come from teams that treat terpenes as powerful bioactive ingredients, not pleasant aromas.

References:

1. University of Arizona Health Sciences.
Cannabis Terpenes Provide Pain Relief and Contribute to the Entourage Effect.
https://healthsciences.arizona.edu/news/releases/study-shows-cannabis-terpenes-provide-pain-relief-contribute-entourage-effect

2. U.S. Food and Drug Administration (FDA).
Botanical Drug Development: Guidance for Industry.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/botanical-drug-development-guidance-industry

3. Centers for Disease Control and Prevention (CDC).
Marijuana and Public Health.
https://www.cdc.gov/marijuana

4. Jiang R. et al.
CYP450 Modulation by Terpenes. Drug Metab Rev. 2023.
https://www.tandfonline.com/doi/abs/10.1080/03602532.2023.2171234